Considerations in the deployment of novel universal vaccines against epidemic and pandemic influenza - Arinaminpathy, N; Riley, S; Barclay, W.S; Saad-Roy, C; Grenfell, B (medRxiv, 2019)
There is increasing interest in the development of new, ‘universal’ influenza vaccines (UIV) that - unlike current vaccines - are effective against a broad range of seasonal influenza strains, as well as against novel pandemic viruses. Even where these vaccines do not block infection, they can moderate clinical severity, reducing morbidity and mortality while potentially also reducing opportunities for transmission. Previous modelling studies have illustrated the potential epidemiological benefits of UIVs, including their potential to mitigate pandemic burden. However, these new vaccines could shape population immunity in complex ways. Here, using mathematical models of influenza transmission, we illustrate two types of unintended consequences that could arise from their future deployment. First, by reducing the amount of infection-induced immunity in a population without fully replacing it, a seasonal UIV programme may permit larger pandemics than in the absence of vaccination. Second, the more successful a future UIV programme is in reducing transmission of seasonal influenza, the more vulnerable the population could become to the emergence of a vaccine-escape variant. These risks could be mitigated by optimal deployment of any future UIV vaccine: namely, the use of a combined vaccine formulation (incorporating conventional as well as multiple universal antigenic targets), and by achieving sufficient population coverage to compensate for reductions in infection-induced immunity. As early candidates of UIVs approach advanced clinical trials, there is a need to monitor their characteristics in such a way that is focused on their potential impact. This work offers a first step in this direction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNA and SR were supported by the UK Medical Research Council and Department for International Development, grant reference: MR/R015600/1. BG acknowledges support from the Bill and Melinda Gates Foundation. CS-R received financial support from the Natural Sciences and Engineering Research Council of Canada, and the James S. McDonnell Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThis manuscript does not generate new primary data, and instead uses mathematical modelling to analyse data already available in the literature